On May 13, 2020 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported that vorasidenib and ivosidenib clinical data will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held virtually May 29-31, 2020 (Press release, Agios Pharmaceuticals, MAY 13, 2020, View Source [SID1234557921]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The accepted abstracts are listed below and are available online on the ASCO (Free ASCO Whitepaper) meeting library website: View Source All oral and poster presentations will be available on demand for registered meeting attendees on the ASCO (Free ASCO Whitepaper) conference website beginning on May 29 at 8:00 a.m. ET.
Oral Presentation:
Title: Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population
Oral Abstract Session: Central Nervous System Tumors
Abstract: 2504
Presenter: Ingo K. Mellinghoff, M.D., Memorial Sloan Kettering Cancer Center
Poster Presentations:
Title: INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation
Poster Session: Central Nervous System Tumors
Abstract: TPS2574
Author: Ingo K. Mellinghoff, M.D., Memorial Sloan Kettering Cancer Center
Title: IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study
Poster Session: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract: 4576
Author: Elia Aguado-Fraile, Ph.D., Agios Pharmaceuticals
Title: Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML)
Poster Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract: 7521
Author: Courtney D. DiNardo, M.D., University of Texas MD Anderson Cancer Center